| INTRODUCTION
Carbamoyl phosphate synthetaseI(CPS1) is a complex multidomain mitochondrial matrix enzyme, which catalyzes the first and limiting step of the urea cycle. 1, 2 Together with a co-factor Nacetylglutamate (NAG) synthesized by N-acetylglutamate synthase, it catalyzes the synthesis of carbamoyl phosphate (CP) using bicarbonate, ATP, and ammonia. 3, 4 CP is a labile high energy phosphate compound, which is the precursor metabolite for two important metabolic pathways, synthesis of arginine (and urea in ureotelic vertebrates) and de novo biosynthesis of pyrimidine. Human gene CPS1 is a large gene located on chromosome 2 q34 and expands more than 120 kb, encompassing 38 exons and 37 introns with an open reading frame of 4503 nucleotides encoding a polypeptide of 1500 amino acids. 3, [5] [6] [7] [8] [9] Its genetic deficiency, carbamoyl phosphate synthetase 1 deficiency (CPS1D, MIM 237300) is a rare autosomal recessive disorder caused by the inborn error of the urea cycle. 10, 11 The defective urea cycle cannot transfer ammonia to urea eventually, leading to toxic hyperammonemia, which is a mortal metabolic disorder with a high morbidity rate. 12, 13 The exact incidence of CPS1D is still unknown, because likely many patients died unreported or/and undiagnosed, but has been estimated in some populations, about 1/800 000 in Japan and 1/539 000 in Finland. [14] [15] [16] [17] Based on age of onset, clinical manifestations and whether CPS1 enzyme activity is absent or residual, CPS1D can be identified as neonatal-onset and late-onset.
Most patients presented neonatal-onset CPS1D, and usually died in soon due to severe hyperammonemia caused encephalopathy. 12, 18, 19 Diagnosis of CPS1D is primarily based on the biochemical measurement of the intermediate metabolites, which, nevertheless, cannot differentiate CPS1D from N-acetylglutamate synthetase deficiency (NAGSD). 20 Therefore, prompt and correct diagnosis of CPS1D needs to be warranted.
Molecular diagnosis plays a paramount role in the diagnosis of CPS1D, especially when plasma amino acid analysis cannot distinguish CPS1D from NAGSD. 10, 20 So far, more than 240 CPS1 pathogenic mutations have been reported and documented in Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ ac/index.php). 3, 11, [21] [22] [23] [24] [25] [26] [27] [28] [29] However, most of the mutations are no-recurrent and only a small fraction of the reported mutations occurred in unrelated patients, indicating the private nature of the mutations, further complicated the diagnosis of CPS1D. 11 Moreover, the molecular diagnosis of CPS1D can be hindered by the large size of the CPS1 gene. [7] [8] [9] 11 With the development and the recent introduction of whole genome sequencing, large amounts of data readily including the whole region of the CPS1 gene and other UCDs causative genes can be generated with lower cost and less effort, offering new opportunities for CPS1D diagnosis. 20, 22, 30 Notably, to our knowledge, only one successful use of whole exome sequencing in the CPS1D diagnosis was reported by Choi et al. in Korean population. 29 Here in the present study, we reported the initial successful application of exome sequencing in two Chinese neonates and identified three novel pathogenic mutations in the CPS1 gene.
| MATERIALS AND METHODS

| Samples
The Case 1 patient was a Chinese boy born after 39 weeks of pregnancy with spontaneous delivery. His parents were healthy. The patient weighed 3510 g at birth. It was noted that the baby had poor feeding and vomited frequently after birth. On the second day, the patient developed sign of deepening encephalopathy, such as unconsciousness and intermittent convulsions of the extremities. 
| Exome sequencing
Exome sequencing of the affected patients was performed according to experimental procedures described previously. 31 Informed consent was signed and collected, and the study protocol was approved by Additionally, a group of 105 Chinese subjects without CPS1D were recruited as controls to test whether the discovered mutations were polymorphisms.
| Analysis of sequencing data
Illumina Sequence Control Software v4.0.4 was used for base calling and quality assessment of sequencing reads. The NextGENe ® was utilized for the alignment of sequencing reads to the reference human genome (GRCh37.3, SNP135). All the single nucleotide variants (SNVs) and insertion-deletions (indels) were saved as VCF format files and uploaded to the online variation annotation tool Ingenuity ® Variant Analysis ™ for predictions of the mutation deleterious effect, genetic and biological analyses, and mutation interpretation.
| Validation of the mutations in the CPS1 gene
Candidate mutations from exome sequencing were validated by polymerase chain reaction (PCR) and Sanger sequencing. Primer 3 (http:// primer3.ut.ee/) was used for the design of primers for the amplification of regions contained candidate mutations in the CPS1 gene (NM_001875). The PCR analysis was performed and the sequencing data were analyzed and exported by Chromas 2.5.1.
| In-silicon analysis of the validated mutations
The pathogenicity predictions for the validated missense mutations were performed using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), (Table 1) . No such mutations were observed in the 105 unrelated healthy individual.
| RESULTS
| Identification and validation of mutations
| In-silicon analysis for the validated mutations
Pathogenicity predictions for the three novel missense mutations were p.Leu1363_Ile1366del is located in the NAG binding site ( Figure 5 ). All these findings suggested that the identified mutations were pathogenic.
| DISCUSSION
CPS1D is a rare autosomal recessive inborn UCD, potentially results in lethal hyperammonemia. 12, 13 Clinical manifestations include hypothermia, vomiting, hypotonia, convulsions, coma, and exitus.
All the CPS1D can be traced back to mutations in the gene encoding the CPS1 enzyme. Since the first identification of mutation in the CPS1 gene, 21 40 Homology modeling showed that p.Cys600Tyr the stability and solubility of the CPS1 protein. 41 It is probably that the p. Pro846Leu mutation would break the connection bridge between the two active catalytic centers, and wreck the structural stability of CPS1 protein. Near the p.Pro846Leu mutation, several mutations have already been found, such as p.Leu843Ser, p.Arg850Cys, and p.Arg850His, which suggests this locus may be a high mutation site and may have a significant effect on the function of the entire protein.
11,32
The substituted amino acids or the deleted amino acids could change the conformation of the CPS1 protein, sequentially damage the enzyme activity of CPS1, consequently resulting in the accumulation of ammonia to toxic levels or even lethal levels in tissues and plasma, especially in the brain, which can cause irreversible brain damage and lead to death of patients due to brain edema. In view of these two Chinese neonatal cases with typical characteristics of CPS1D, we determined that these three novel missense mutations were pathogenic. However, it is still necessary to carry out further functional studies to clarify the molecular pathogenesis of the novel mutations.
To conclude, we originally and successfully applied exome sequencing to the diagnosis of CPS1D in Chinese population, suggest- 
